Form 4: VolitionRX Director Alan Colman Amends Stock Options

Director Alan Colman amended stock options at VolitionRX on January 29, 2025, involving the cancellation of old options and the grant of replacement options.

Summary

• On January 29, 2025, Alan Colman, a director of VolitionRX Ltd, engaged in a transaction involving stock options.
• The transaction involved the amendment of existing stock options.
• This resulted in the deemed cancellation of 'old' options and the grant of 'replacement' options.
• The exercise price for both the old and replacement options is $3.25.
• The old options, originally granted on February 11, 2019, were fully vested and exercisable 12 months from the grant date, expiring five years from the first exercisable date.
• The replacement options are fully vested and expire on February 11, 2029, which is ten years from the original grant date.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option amendments, with no inherent positive or negative sentiment.

Industry Context

This is a standard Form 4 filing related to insider transactions, common in publicly traded companies. It provides transparency regarding changes in beneficial ownership of securities.

Stakeholder Impact

• The amendment of stock options may have a minor impact on shareholders by potentially affecting the dilution of shares.

Key Dates